TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Quetiapine Fumarate Sustained Release in Major Depression With Comorbid Fibromyalgia Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with a DSM IV diagnosis of major depression and fibromyalgia confirmed by using the American College of Rheumatology criteria. Male or female between the ages of 18 and 65.~* Patients who score at least 22 on the 17-item HAM-D scale and at least 4 (i.e., moderately ill) on the Clinical Global Impression (CGI) severity scale. Both criteria have to be met at screening and baseline (Study Day 0).~Exclusion Criteria:~* Patients with DSM-IV Axis 1 disorder other than MDD and Chronic Pain Disorder within 6 months of enrolment.~* History of inadequate response to adequate treatment (6 weeks) with 2 or more classes of antidepressants during current depressive episode.~* Patients who, in the investigator's opinion, pose a risk for suicide.~* History of suicide attempt within 3 years of entering study.~* Current depressive episode secondary to general medical condition excluding Fibromyalgia.~* History or presence of bipolar disorder or psychosis.~* Post traumatic stress disorder, anorexia nervosa or bulimia nervosa.~* Patients with diagnosis of DSM-IV Axis II disorder which has a major impact on the patient's current psychiatric status.~* Present DSM IV diagnosis of substance abuse or dependence within 6 months prior of the screening visit (except dependence in full remission, and except caffeine, nicotine or opiate dependence)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Quetiapine Fumarate Sustained Release(Seroquel SR)50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator, using patient tolerance and response as guidelines over the duration of the trial.
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or non-pregnant, non-lactating females greater than or equal to (≥) 18 years old.~* In remission from demonstrated overt HE (Conn score 0 or 1).~* Have had one or more episodes of overt HE associated with cirrhosis within 6 months prior to screening visit (Day -7 to -1).~* Participant has a close family member or other personal contact who is familiar with the participant's HE and can provide continuing oversight to the participant and is willing to perform as caregiver for the participant during the conduct of the trial.~Exclusion Criteria:~* Participant has been diagnosed with human immunodeficiency virus (HIV) as determined by medical history.~* History of tuberculosis infection.~* Participant has been diagnosed with chronic respiratory insufficiency.~* Participant has been diagnosed with a current infection for which they are currently taking oral or parenteral antibiotics.~* Renal insufficiency requiring routine dialysis.~* Participant has an active spontaneous bacterial peritonitis(SBP) infection.~* Intestinal obstruction or inflammatory bowel disease.~* Participant has active malignancy within the last 5 years prior to screening visit, except basal cell carcinoma of the skin, or if female, in situ cervical carcinoma that has been surgically excised.~* Current gastrointestinal (GI) bleeding or has a history of a GI hemorrhage of sufficient severity to require hospitalization and a transfusion of ≥2 units of blood within 3 months prior to screening visit.~* Participant is anemic, as defined by a hemoglobin of less than (\<) 8 grams/deciliter (g/dL).~* Scheduled to receive a liver transplant within 1 month of screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rifaximin 550 mg BID (Type: EXPERIMENTAL): Participants will receive rifaximin 550 milligrams (mg) tablet orally twice daily (BID) for 24 weeks.
- Rifaximin 550 mg BID + Lactulose (Type: EXPERIMENTAL): Participants will receive rifaximin 550 mg tablet orally BID with lactulose solution for 24 weeks. Lactulose dose will be self-titrated by the participant to produce 2 to 3 soft stools per day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic or recurrent carcinoma of the esophagus or gastroesophageal junction~  * Squamous cell carcinoma OR~ * Adenocarcinoma~* No known brain metastases~PATIENT CHARACTERISTICS:~Age:~* 18 to 100~Performance status:~* Zubrod 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Not specified~Renal:~* Creatinine no greater than 1.5 times upper limit of normal~Cardiovascular:~* No uncontrolled hypertension~* No unstable angina~* No symptomatic congestive heart failure~* No myocardial infarction within the past 6 months~* No serious uncontrolled cardiac arrhythmia~Gastrointestinal:~* No active inflammatory bowel disease~* No significant bowel obstruction~* No chronic diarrhea~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No active infection requiring systemic therapy~* No other prior malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 28 days since prior biologic therapy~* No prior biologic therapy for metastatic or recurrent disease~* No concurrent sargramostim (GM-CSF)~* No concurrent immunotherapy for tumor~Chemotherapy:~* At least 28 days since prior chemotherapy~* No prior chemotherapy for metastatic or recurrent disease~* No prior gemcitabine or irinotecan~* Prior adjuvant or neoadjuvant chemotherapy at time of initial diagnosis of localized disease allowed~* No other concurrent chemotherapy for tumor~Endocrine therapy:~* See Disease Characteristics~* At least 28 days since prior endocrine therapy~* No prior endocrine therapy for metastatic or recurrent disease~* No concurrent hormonal therapy for tumor~Radiotherapy:~* At least 28 days since prior radiotherapy~* No prior radiotherapy for metastatic or recurrent disease~* Prior adjuvant or neoadjuvant radiotherapy at time of initial diagnosis of localized disease allowed~* No concurrent radiotherapy for tumor~Surgery:~* Prior thoraco-abdominal surgery allowed~* At least 3 weeks since prior surgery and recovered~Other:~* No other concurrent anti-cancer therapy for tumor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gemcitabine + Irinotecan (Type: EXPERIMENTAL): Gemcitabine 1000mg/m2 IV over 30 min on Days 1,8 q21days; Irinotecan 100mg/m2 IV over 90 min on Days 1,8 q21days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Ferinject® on Anemia and Transfusion Rates After Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients admitted for elective cardiac surgery under cardiopulmonary bypass, with no exclusion criteria, and having signed an informed consent, will be enrolled in the study.~Exclusion Criteria:~* Patients \< 18 years~* Urgent surgery~* Off-pump cardiac surgery~* Redo cardiac surgery~* Preoperative anemia (Hb \< 10g/l or Ht \< 30%)~* Transfusion within 72h preoperatively~* Pregnancy~* History of asthma or other specific allergies~* History of allergy to iron~* Acute infection~* Hepatic insufficiency~* Renal insufficiency (creatinine Clearance \< 30ml/min)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ferric Carboxymaltose group (Type: ACTIVE_COMPARATOR): Ferric carboxymaltose group will receive 1g of Ferric carboxymaltose at day 1 following cardiac surgery
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo group will receive 100 mL of IV isotonic serum saline at day 1 following cardiac surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SAT vs Escitalopram for Rectal Hypersensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All patients must fulfill the diagnostic criteria for IBS-C (Rome III) as defined below and have rectal hypersensitivity (see below).~* Patients must report recurrent abdominal pain or discomfort for at least 3 days per month in the last 3 months with two or more of the following symptoms:~  * Improvement with defecation; and/or~ * Onset associated with a change in frequency of stool; and/or~ * Onset associated with a change in form (appearance) of stool~* No structural diseases~* On a diary:~  * Pain/discomfort for at least 2 days/week;~ * No loose or watery stool \<25% of bowel movements.~Exclusion Criteria:~* Patients with mixed-IBS.~* Patients currently on SSRI or MAO inhibitors. Patients on stable doses of other antidepressants will be included provided the dose is unchanged during study.~* Patients taking drugs that are constipating, (e.g.; calcium channel antagonists will either be excluded or drug discontinued)~* Patients with co-morbid illnesses; severe cardiac disease, chronic renal failure or previous gastrointestinal surgery except cholecystectomy and appendectomy.~* Neurologic diseases e.g.; head injury, epilepsy, multiple sclerosis, strokes, spinal cord injuries.~* Impaired cognizance (mini mental score of \< 15) and/or legally blind.~* Pregnant or likely to conceive during the course of the study. Women with potential for pregnancy must be willing to use contraceptive measures during the study. Urinary pregnancy tests will be performed on such women prior to any radiologic procedures.~* Hirschsprung's disease.~* Alternating constipation and diarrhea (22).~* Ulcerative/Crohns colitis.~* Previous pelvic surgery, rectocele/bladder repair, radical hysterectomy, anal surgery.~* Rectal prolapse or anal fissure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sensory Adaptation training (Type: ACTIVE_COMPARATOR): a large compliant balloon is placed in the rectum attached to a barostat. The balloon is distended in 1 mm increments until patient reports moderate discomfort and then increased in 1 mm increments until maximum tolerable pressure. Gradually over 6 training sessions, administered biweekly, the maximum tolerable pressure is increased over 3 months, if treatment is successful.
- Escitalopram Therapy (Type: EXPERIMENTAL): Patients randomized to this arm will receive daily 10 mg escitalopram for 3 months. If the medication is effective their bowel symptoms and pain thersholds will improve.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of a Novel Antipsychotic ITI-007 in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patient's age is 18-55~* Patient has current diagnosis of schizophrenia and is experiencing an acute exacerbation of psychosis~* Patient has a history of at least three months exposure to one or more antipsychotic therapy(ies) and a prior response to antipsychotic therapy within the previous five years~Exclusion Criteria:~* Any female patient who is pregnant or breast-feeding~* Any patient presenting with concurrent dementia, delirium, mental retardation, epilepsy, drug-induced psychosis, or history of significant brain trauma~* Any patient presenting with schizoaffective disorder, bipolar disorder, acute mania, or major depression with psychotic features~* Any patient considered to be an imminent danger to themselves or others~* Any patient with hematological, renal, hepatic, endocrinological, neurological, or cardiovascular disease or substance abuse as defined by protocol~* Any patient judged by the Investigator to be inappropriate for the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- ITI-007 Low Dose (Type: EXPERIMENTAL): None
- ITI-007 High Dose (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Risperidone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Interferon-Gamma on Cavitary Pulmonary Tuberculosis in the Lungs

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Positive acid-fast bacillus (AFB) smear within 14 days prior to randomization~* Cluster of Differentiation 4 greater than 200 if HIV positive~* Ability to sign consent~* Bilateral, cavitary pulmonary TB~Exclusion Criteria:~* Multidrug-resistant (MDR) TB~* Extrapulmonary TB~* HIV positive with opportunistic infection within 30 days of study entry~* Cancer~* Asthma~* Pregnant or lactating women~* Chronic heart disease~* Chronic liver disease~* Chronic renal disease~* Seizure disorder~* Bleeding or clotting disorder~* Diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Standard Treatment (Type: PLACEBO_COMPARATOR): Isoniazid, Rifampin, Pyrazinamide Anti-Tuberculous Therapy
- Aerosol Interferon-gamma (Type: EXPERIMENTAL): Aerosol Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide
- Subcutaneous Interferon-Gamma (Type: EXPERIMENTAL): Subcutaneous Interferon-Gamma plus Isoniazid, Rifampin, and Pyrazinamide

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Racial Differences in Vagal Control of Glucose Homeostasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* African American or white (race will be self-defined, but only subjects who report both parents of the same race will be included)~* 18-60 years old~* BMI 30-45 Kg/m2~* Not pregnant or breastfeeding~Exclusion Criteria:~* Pregnant or breastfeeding~* Diabetes diagnosis (defined by the American Diabetes Association (ADA) criteria)38~* Cardiovascular disease such as myocardial infarction within 6 months prior to enrollment, presence of angina pectoris, significant arrhythmia, congestive heart failure (LV hypertrophy acceptable), deep vein thrombosis, pulmonary embolism, mitral valve stenosis, aortic stenosis, or hypertrophic cardiomyopathy.~* Arrhythmia (first-, second-, and third-degree atrioventricular (AV) block)~* Significant weight change \>5% in the past 3 months~* Impaired hepatic function (AST and/or Alanine transaminase (ALT) \> one and one half times (1.5X) upper limit of normal range)~* Impaired renal function (eGFR \<60ml/min)~* Users of strong inhibitors of Cytochrome P450 3A4 (CYP3A4) or cytochrome P450, family 2, subfamily D, polypeptide 6 (CYP2D6)~* Users of other acetylcholinesterase inhibitors such as pyridostigmine or bethanechol~* History of alcohol or drug abuse~* Mental conditions rendering the subject unable to understand the nature, scope, and possible consequences of the study~* Inability to comply with the protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Galantamine 16 mg then placebo (Type: EXPERIMENTAL): Galantamine 16 mg po one time dose then placebo on 2nd visit
- Placebo then Galantamine 16 mg (Type: PLACEBO_COMPARATOR): Placebo capsule po one time dose then Galantamine 16 mg on 2nd visit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria (Part 3):~* Patients should have received at least two prior treatment regimens.~* Confirmed refractory MM (measurable disease) or PCL. Patients must be refractory to treatment with both lenalidomide/dexamethasone and bortezomib/dexamethasone (or to treatment with bortezomib/lenalidomide/dexamethasone), defined as documented progressive disease on therapy or within 60 days of completing treatment with these regimens.~* Previously received adequate alkylator therapy.~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.~* Adequate hematology laboratory values without transfusion support within 2 weeks of screening.~* Adequate liver and renal function.~* Additional criteria exist.~Key Exclusion Criteria (Part 3):~* Primary amyloidosis.~* Concomitant malignancies or previous malignancies with less than a 3-year disease free interval at the time of enrollment (patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or Stage A low grade prostate cancer may enroll irrespective of the time of diagnosis).~* Autologous or allogeneic stem cell or bone marrow transplant within 3 months prior to first dose of study drug.~* Cytotoxic therapy or monoclonal antibodies within 21 days prior to first dose of study drug.~* Radiotherapy within 21 days prior to first dose of study drug (if the radiation portal covered ≤ 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy).~* Corticosteroid doses \> 10 mg/day of prednisone or equivalent within 2 weeks prior to first dose of study drug.~* Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or active hepatitis C.~* Additional criteria exist.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ARRY-520 (Type: EXPERIMENTAL): None
- ARRY-520 + G-CSF support (Type: EXPERIMENTAL): None
- ARRY-520 + dexamethasone + G-CSF support (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Medical Management of Late Intrauterine Death.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Closed cervix without evidence of cervical dilation or baseline uterine activity.~* A Bishop score of \<5, having intact membranes.~* Gestation greater than or equal to 20 weeks established by the date of menstruation or by fetometry and ultrasound-confirmed late IUFD.~Exclusion Criteria:~* Multiple pregnancies.~* IUFD after late foeticide or the management of specific medical conditions associated with an increase in the risk of IUFD.~* Patients with a history of hypertension.~* Women with a history of unexplained antepartum haemorrhage, pelvic dystocia or any another counter-indications where medications were used.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- isosorbide dinitrate-oxytocin (Type: EXPERIMENTAL): Preinduction with isosorbide dinitrate gel solution (80 mg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.~If the cervical conditions (\<7 Bishop Score) did not change after the treatment application, a new dose, without exceeding 4 doses, to facilitate cervical ripening.
- misoprostol-oxytocin (Type: PLACEBO_COMPARATOR): Preinduction with misoprostol gel solution (100 mcg/1.5 mL) were administered in the posterior fornix every 3 hours. Once a Bishop score of over 7 was reached, oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.~If the cervical conditions (\<7 Bishop score) did not change after the treatment application, participants received a new dose, without exceeding 4 doses, to facilitate cervical ripening.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete